Basic Information
| LncRNA/CircRNA Name | DBH-AS1 |
| Synonyms | NA |
| Region | GRCh38_9:133654586-133657313 |
| Ensemble | ENSG00000225756 |
| Refseq | NR_002783 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Western blot, Luciferase assay, RIP |
| Sample | hepatocellular carcinoma tissues, cell line (Huh7, PLC, HepG2, Hep3B, LO2) |
| Expression Pattern | up-regulated |
| Function Description | DBH-AS1 expression was upregulated and miR-138 expression was downregulated in HCC tissues and cells. DBH-AS1 silencing and miR-138 overexpression reduced cell viability, inhibited colony formation, and induced apoptosis. DBH-AS1 overexpression attenuated miR-138-mediated anti-proliferation and pro-apoptosis effects. high level of DBH-AS1 was significantly correlated with tumor size (P = 0.025), TNM stage (P = 0.014) and lymph node metastasis. |
| Pubmed ID | 30142544 |
| Year | 2018 |
| Title | LncRNA DBH-AS1 facilitates the tumorigenesis of hepatocellular carcinoma by targeting miR-138 via FAK/Src/ERK pathway. |
External Links
| Links for DBH-AS1 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |